Akcea Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Akcea Therapeutics's estimated annual revenue is currently $64.9M per year.
- Akcea Therapeutics's estimated revenue per employee is $188,567
- Akcea Therapeutics's total funding is $668.2M.
- Akcea Therapeutics has 344 Employees.
- Akcea Therapeutics grew their employee count by 46% last year.
- Akcea Therapeutics currently has 19 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Akcea Therapeutics?
Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea () is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence. http://www.fiercebiotech.com/story/isis-launches-cardio-subsidiary-and-recruits-genzyme-vet-run-it/2015-01-07keywords:N/A
Number of Employees
Employee Growth %
|Ken Bush||Regional Case Manager|
|Kari Hanson||Manager, Rare Disease|
|Nancy Johansen||Director Global Regulatory Affairs||Email Available|
|Victoria Bartlett||Director Of Alliance And Program Management|
|Victoria Drizin||Manager, OS & Sr. Exec. Assistant|
|Paul Schmidt||Head of Financial Planning & Analysis|
|Todd Amrhein||Associate Director, Global Training, Learning, & Development||Email Available|
|Christine Goldsberry||Regional Account Manager|
|Dan Moynihan||Chief Compliance Officer||Email Available|
|Rebecca Archer||Nurse Case Manager||Email Available|
Akcea Therapeutics News
Liver Therapy Forum weekly digest provides an overview on what's happening in liver diseases in 2019. This week's spotlight is Akcea ...
In its most recent trading session, Akcea Therapeutics, Inc. (AKCA) dropped by -1.5% – here is what that looked like (as of 2019-08-23): ...
Akcea Therapeutics Inc (NASDAQ:AKCA) has received an average recommendation of “Hold” from the eight ratings firms that are currently ...
Akcea Therapeutics Executive Hires
|2016-01-20||Louis St. L. O'Dea||Chief Medical Officer||Article|
|2017-10-05||Nelly Komari||Medical Director||Article|